Cargando…
Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency
Esophageal cancer is a cancer with poor prognosis and the standard 1(st) line treatment for metastatic or recurrent EC is systemic chemotherapy with doublet chemotherapy based on platinum and 5-fluorouracil (5-FU). However, 5-FU could be a source of severe treatment-related toxicities due to deficie...
Autores principales: | Schmitt, Antonin, Royer, Bernard, Boidot, Romain, Berthier, Joseph, Ghiringhelli, François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319454/ https://www.ncbi.nlm.nih.gov/pubmed/37409256 http://dx.doi.org/10.3389/fonc.2023.1187052 |
Ejemplares similares
-
Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure
por: Dolat, Marine, et al.
Publicado: (2020) -
Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency
por: van Staveren, Maurice C., et al.
Publicado: (2011) -
Delayed Presentation of DPD Deficiency in Colorectal Cancer
por: Law, Lindsey, et al.
Publicado: (2014) -
Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma
por: Akhter, Khaleda, et al.
Publicado: (2019) -
Immune effects of 5-fluorouracil: Ambivalence matters
por: Ghiringhelli, François, et al.
Publicado: (2013)